Vivo Bio Tech Ltd

📊 Vivo Bio Tech FY2026 Results: Revenue Up, But Challenges Persist

- Board of Directors approved Audited Standalone & Consolidated Financial Results for Q4 and year ended March 31, 2026.

- Reappointment of Mr. Kalyan Ram Mangipudi as Whole-time Director for 5 years from July 29, 2026, subject to shareholder approval.

- Approval of Material Related Party Transactions, subject to shareholder approval via Postal Ballot.

- Appointment of consultant/advisor for proposed Scheme of Arrangement/Amalgamation.

- Standalone Revenue from operations for Q4 2026: Rs. 1,376.72 Lacs, Yearly: Rs. 5,256.84 Lacs.

- Standalone Net Profit (Loss) for Q4 2026: (Rs. 543.69) Lacs, Yearly: (Rs. 193.61) Lacs.

- Consolidated Revenue from operations for Q4 2026: Rs. 1,420.11 Lacs, Yearly: Rs. 5,333.47 Lacs.

- Consolidated Net Profit (Loss) for Q4 2026: (Rs. 516.27) Lacs, Yearly: (Rs. 170.88) Lacs.

- Significant increase in Fixed Assets: Standalone Rs. 6,843.91 Lacs, Consolidated Rs. 7,179.93 Lacs as of March 31, 2026.

- Outstanding statutory dues: Provident Fund Rs. 60.73 Lacs, ESI Rs. 6.37 Lacs, Professional Tax Rs. 11.26 Lacs, TDS Rs. 151.29 Lacs, Income Tax Rs. 189.64 Lacs.

- Audit reports by P. Murali & Co. with unmodified opinion for both standalone and consolidated financial results.